- Home
- CSX vs ALNY Comparison
CSX vs ALNY Comparison
Compare CSX & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSX
- ALNY
- Stock Information
- Founded
- CSX 1978
- ALNY 2002
- Country
- CSX United States
- ALNY United States
- Employees
- CSX N/A
- ALNY N/A
- Industry
- CSX Railroads
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- CSX Industrials
- ALNY Health Care
- Exchange
- CSX Nasdaq
- ALNY Nasdaq
- Market Cap
- CSX 66.1B
- ALNY 59.1B
- IPO Year
- CSX N/A
- ALNY 2004
- Fundamental
- Price
- CSX $32.53
- ALNY $452.00
- Analyst Decision
- CSX Buy
- ALNY Strong Buy
- Analyst Count
- CSX 23
- ALNY 27
- Target Price
- CSX $36.78
- ALNY $416.50
- AVG Volume (30 Days)
- CSX 24.2M
- ALNY 1.1M
- Earning Date
- CSX 10-15-2025
- ALNY 10-30-2025
- Dividend Yield
- CSX 1.60%
- ALNY N/A
- EPS Growth
- CSX N/A
- ALNY N/A
- EPS
- CSX 1.63
- ALNY N/A
- Revenue
- CSX $14,155,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- CSX N/A
- ALNY $58.97
- Revenue Next Year
- CSX $4.56
- ALNY $38.81
- P/E Ratio
- CSX $19.95
- ALNY N/A
- Revenue Growth
- CSX N/A
- ALNY 5.01
- 52 Week Low
- CSX $26.22
- ALNY $205.87
- 52 Week High
- CSX $37.25
- ALNY $469.81
- Technical
- Relative Strength Index (RSI)
- CSX 35.65
- ALNY 66.64
- Support Level
- CSX $31.91
- ALNY $441.50
- Resistance Level
- CSX $33.20
- ALNY $458.30
- Average True Range (ATR)
- CSX 0.97
- ALNY 11.20
- MACD
- CSX -0.29
- ALNY -4.69
- Stochastic Oscillator
- CSX 11.61
- ALNY 37.09
About CSX CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $14.5 billion in 2024. On its more than 21,000 miles of track, CSX hauls shipments of coal (16% of consolidated revenue), chemicals (17%), intermodal containers (16%), automotive cargo (7%), and a diverse mix of other bulk and industrial merchandise.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.